SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
REGN
An SI Board Since March 1997
Posts SubjectMarks Bans Symbol
18 1 0 REGN
Emcee:  K.J.Devine Type:  Unmoderated
Started By: K.J.Devine
Date: Mar 9 1997 2:58PM EST

Amgen-Regeneron. Takeover possible by second quarter 1997. Amgen will take over "REGN", team up to to test DNF based products.

Amgen-Regeneron Partners as a treatment for ALS, delivered Intrathecally (directly into the spinal fluid), a route of delivery that may yield better results than subcutaneous delivery. Amgen is also testing BDNF in early stage, small European trials on Guillain
Barre syndrome and diabetic neuropathy. Both these conditions involve peripheral neurons, which may allow for successful treatment via subcutaneous delivery. Amgen is conducting an early-stage NT-3 trial in diabetic neuropathy on behalf of Amgen-Regeneron Partners and plans to start a trial in chemotherapy-induced neuropathy during the first half of 1997. The company anticipates announcing preliminary
results of the NT-3 diabetic neuropathy study later in 1997.

Amgen said that ongoing preclinical studies with glial derived neurotrophic factor(GDNF)in Parkinson's disease are continuing to yield encouraging results that support the rationale for ongoing clinical development of the drug in this disease and Phase 1
safety data is expected by year end. Amgen previewed early preclinical research in protection against hearing loss, a significant disability for 25 million people in the United States.

Procter & Gamble invested $10 million in the company and will support $3.75 million of annual research at Regeneron for up to five years.

In addition, annual payments are expected from Procter & Gamble for research support and from Merck & Co. Inc. for contract manufacturing of an intermediate for an approved Merck pediatric vaccine. "

Regeneron's total revenue in the fourth quarter of 1996 increased to $6.5 million from $5.7. million in the same period of 1995. The increase was due to higher investment income and an increase in contract manufacturing revenue from a long-term manufacturing agreement with Merck & Co. Inc.

K.J.Devine
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
18 shdu, From when is s-TNF-alfa-r antibody (IMNX) protease inhibitor?????? You sMiljenko Zuanic-6/10/1997
17 John, Sorry, I don't know Paracelsian very well. I read through their homeshdu-6/10/1997
16 Sam: Please forgive my intrusion but have been trying to find latest info re trJOHN F. MORGAN-5/15/1997
15 Try the other thread, the REGENERON thread.......scaram(o)uche-5/14/1997
14 GOOD NEWS!! I CANT WAIT TIL THE OPENING ON WEDNESDAY!!! IT MAY OPEN AT 14 +++++sean-5/13/1997
13 Im surprised no one posted this news today: P&G And Regeneron Form 10-YearTracker-5/13/1997
12 Got this from a friend (thanks, Mike). Being downstream in the signaling pathwscaram(o)uche-4/8/1997
11 Rick, Agreed. REGN has over 300 employees with production plant worth over 20MMiljenko Zuanic-4/6/1997
10 Richard, I agree with you that most projects in biotechs have rational scientishdu-4/6/1997
9 Sam: Your comments would imply that most projects at companies like Sugen, Ariscaram(o)uche-4/5/1997
8 Yes Richard, they have to be intracellular or at least membrane associated. Othshdu-4/5/1997
7 Sam..... Do you think that molecules need be extracellular or membrane-associascaram(o)uche-4/5/1997
6 April 5 announcement of MAP kinase is a non-event. There are so many kinases. Jshdu-4/5/1997
5 Well, not to take away anything that K. J. Devine started... And I'm prettPatrick Slevin-4/5/1997
4 Yes, they are very good at marketing, but they have nothing in the inventory thshdu-4/5/1997
3 From a marketing point of view I think the company is well-connected and has grPatrick Slevin-4/4/1997
2 Regeneron is a one man show, namely George Yancapolos, the chief scientist. He shdu-4/4/1997
1 Okay, I'll take the bait. Why do you think Amgen will take over REGN? I knPatrick Slevin-3/24/1997
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):